Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab for Non-histaminergic Angioedema with Normal C1-INH
NCT04206605Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in non-histaminergic angioedema with normal C1-inhibitor comparing Lanadelumab with Placebo (2 arms). Primary endpoint: Number of Investigator-Confirmed Angioedema Attacks. Started May 2020; status: completed.
02
Drugs
lanadelumab
03
Conditions
non-histaminergic angioedema with normal C1-inhibitor
Beyond the preview
Go deeper on NCT04206605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206605.